Strides Pharma Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: ₹792.05 High: ₹816.65
on August 8, 2025

52 Week Range

Low: ₹513.05 High: ₹1,675.00
on April 7, 2025
on October 17, 2024

All-Time High: ₹1,675.00 on October 14, 2024

Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights

Key Statistics

Market Cap i INR73.7B
EPS i 37.06
P/E Ratio (TTM) i 21.59
Forward P/E i 12.43
P/B Ratio i 2.89
PEG Ratio i 12.43
Div. Yield i 0.74%
ROE i 138.93%
Beta i 0.569
Debt to Equity i 72.67

Financial Highlights

Profitability

Gross Margin i 60.32%
Operating Margin i 15.11%
Profit Margin i 7.38%

Returns and Earnings

Return on Assets (TTM) i 59.41%
Return on Equity (TTM) i 138.93%
EBITDA i INR8.5B
Net Income (TTM) i INR3.4B

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i INR502.45
Quarterly Revenue Growth (YoY) i 3.00%
Quarterly Earnings Growth (YoY) i 41.90%

Dividend Information

Last 12-Month Dividend i ₹6.50
Current Dividend Yield i 0.74%
3-Year Average Dividend Yield i 0.32%
3-Year Average Annual Dividend i ₹2.67
3-Year Total Dividends i ₹8.00
Ex-Dividend Date i July 22, 2025

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Strides Pharma STAR 73.74B Mid-cap-3.84%-7.07%26.63%9.57%14.21%-29.61%130.32%44.47%
Sun Pharmaceutical SUNPHARMA 3.92T Large-cap-2.63%-5.12%-10.20%-8.38%-16.03%-8.55%73.73%198.65%
Divi's Laboratories DIVISLAB 1.63T Large-cap-7.03%-14.75%-0.77%-0.41%-2.61%22.45%58.73%91.42%
Alembic APLLTD 184.02B Mid-cap-2.38%-6.43%3.77%5.42%-10.75%-15.92%45.65%-8.45%
Jubilant Pharmova JUBLPHARMA 174.95B Mid-cap-5.02%-5.59%24.87%10.08%1.88%27.78%214.12%81.50%
Natco Pharma NATCOPHARM 165.30B Mid-cap-2.50%-7.83%13.12%-29.19%-35.03%-36.97%40.23%9.43%

Ownership & Short Interest

Insider Ownership i 32.93%
Institutional Ownership i 24.51%
Shares Short i N/A
Short Ratio i N/A
Short % of Shares Outstanding i N/A
Average 10-Day Volume i 646K
Average 90-Day Volume i 533K

Strides Pharma Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Strides Pharma would have performed over time.

INR
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

In the last 52 weeks, Strides Pharma reached a high of ₹1,675.00 (on October 17, 2024) and a low of ₹513.05 (on April 7, 2025).
Curious about Strides Pharma's size and valuation? Its market capitalization stands at 73.74B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.59, and the forward P/E (looking ahead) is 12.43.
Yes, Strides Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.74%, and the company has paid an average of ₹2.67 per share annually over the past 3 years.

When looking at Strides Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Sun Pharmaceutical
SUNPHARMA
3.92THealthcareDrug Manufacturers - Specialty & Generic-8.55%73.73%
Divi's Laboratories
DIVISLAB
1.63THealthcareDrug Manufacturers - Specialty & Generic22.45%58.73%
Alembic
APLLTD
184.02BHealthcareDrug Manufacturers - Specialty & Generic-15.92%45.65%
Jubilant Pharmova
JUBLPHARMA
174.95BHealthcareDrug Manufacturers - Specialty & Generic27.78%214.12%
Natco Pharma
NATCOPHARM
165.30BHealthcareDrug Manufacturers - Specialty & Generic-36.97%40.23%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

To get a sense of Strides Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 138.93%, the Debt to Equity ratio from the most recent quarter is 72.67, and its Gross Profit Margin stands at 60.32%.
Looking at Strides Pharma's growth, its revenue over the trailing twelve months (TTM) was INR46B. Compared to the same quarter last year (YoY), quarterly revenue grew by 3.00%, and quarterly earnings saw a YoY growth of 41.90%.
Wondering who owns Strides Pharma stock? Company insiders (like executives and directors) hold about 32.93% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.51%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.